Medtronic PLC (MDT) - Stock Report

Medtronic's most recent reported period is Q4 FY26, ended 24 April 2026 and released 3 June 2026. Q4 revenue was $9.807 bn, up 9.9% as reported and 6.6% organic; reported diluted EPS was $0.96, up 17.1%, while adjusted diluted EPS was $1.55, down 4.3% — the Q4 adjusted bridge includes gross operating add-backs of $409 m amortization, $118 m restructuring, $77 m acquisition/divestiture items and $23 m litigation, plus a separate $259 m net tax charge, so the reported rise reflects lower year-over-year charges rather than operating acceleration. Revenue was ahead of implied guidance, and adjusted EPS beat company guidance, but Source B's $1.56 Street consensus means adjusted EPS missed by $0.01, or roughly 0.6%. FY26 revenue reached $36.364 bn, up 8.4% as reported and 5.8% organic, while reported operating profit was $6.467 bn and adjusted operating profit was $8.856 bn. Cash quality improved but remains the valuation test: FY26 operating cash flow of $7.330 bn less $1.904 bn of property, plant and equipment additions left company-reported free cash flow of $5.426 bn, against $3.639 bn of dividends and $1.035 bn of buybacks. FY27 guidance calls for 6.75% to 7.25% organic revenue growth and adjusted diluted EPS of $5.90 to $6.00, including the full-year Diabetes business before separation.

The key macro issue is not procedure-volume recovery in isolation, but whether hospital utilization, tariff offsets and reimbursement pressure allow Medtronic’s organic growth to pass through into reported margin and post-capex cash; if they do, the Diabetes separation can sharpen a covered cash-compounding story, and if they do not, the same growth remains an adjusted-earnings narrative with tighter dividend and reinvestment room.

Medtronic is a diversified medical-device company organized around Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company sells implantable and procedural devices, capital-supported systems, consumables, monitoring products, and diabetes technology through direct sales teams, hospital relationships, distributors, and consignment inventory at care sites. This is not a single-product device story; it is a scale healthcare-technology platform with many procedure categories, long regulatory cycles, and a cash engine tied to recurring patient volumes.

The value stack starts with clinical credibility and installed workflows. Cardiovascular brings cardiac rhythm management, ablation, structural heart, aortic, coronary, peripheral vascular, and renal-denervation exposure. Neuroscience contributes spine, cranial, neuromodulation, neurovascular, and specialty therapy platforms where physician training and procedure familiarity matter. Medical Surgical supplies surgical and endoscopy tools, acute care, monitoring, and respiratory products. Diabetes, now being separated as MiniMed, is the growth and portfolio-simplification test: its pumps, sensors, algorithmic insulin delivery, and service model can command a different investor lens if they stand alone with clean cash conversion.

Regulation is central to the model, not background noise. FDA submissions, European medical-device rules, quality systems, product corrections, reimbursement pressure, and hospital procurement discipline determine how quickly innovation reaches revenue and whether it earns attractive margins. The valuation question is therefore sector-specific: can Medtronic sustain procedure-driven growth and product-cycle innovation while funding R&D, quality systems, tuck-in M&A, dividends, and the Diabetes separation from organic cash flow.